Metraipolis › archive › dc_c8c2cb1bfda1

Efficacy and safety analysis of the use of ibrutinib associated with rituximab for the first-line treatment of patients with chronic lymphocytic leukaemia — Europe PMC PMID:41401713

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41401713
DOI
10.1016/j.htct.2025.106234
License (as archived)
solo-consultazione
Archived
2026-11-07T15:56:59.385Z
SHA-256 of the archived text
14dd9091c8e8f78b5af7e58ca93dcdd57f8c4c632b7acaa865cab7d9fe0b31e8
Stable URL of this page
https://metraipolis.com/documento/dc_c8c2cb1bfda1

How to cite

Efficacy and safety analysis of the use of ibrutinib associated with rituximab for the first-line treatment of patients with chronic lymphocytic leukaemia — Europe PMC PMID:41401713 — Europe PMC (en), https://europepmc.org/article/MED/41401713 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c8c2cb1bfda1 (Metraipolis archive dc_c8c2cb1bfda1, sha256 14dd9091c8e8f78b5af7e58ca93dcdd57f8c4c632b7acaa865cab7d9fe0b31e8)
BibTeX
@misc{dcc8c2cb1bfda1,
  title = {Efficacy and safety analysis of the use of ibrutinib associated with rituximab for the first-line treatment of patients with chronic lymphocytic leukaemia — Europe PMC PMID:41401713},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41401713},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c8c2cb1bfda1; sha256 14dd9091c8e8f78b5af7e58ca93dcdd57f8c4c632b7acaa865cab7d9fe0b31e8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41401713. Agents can read the archived copy with the MCP tool read_document.